Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 131.79% from the stock’s current price.

A number of other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings cut Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company initiated coverage on Pyxis Oncology in a research note on Monday, August 3rd. They issued an “overweight” rating and a $12.00 price target for the company. Wedbush assumed coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Leerink Partners reduced their price objective on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Pyxis Oncology Trading Up 0.3%

Pyxis Oncology stock opened at $3.02 on Tuesday. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55. The company has a market capitalization of $191.32 million, a price-to-earnings ratio of -2.14 and a beta of 1.31. The business’s fifty day simple moving average is $2.58 and its two-hundred day simple moving average is $1.98.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, equities research analysts predict that Pyxis Oncology will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the stock. Laurion Capital Management LP lifted its holdings in shares of Pyxis Oncology by 32.3% during the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after buying an additional 1,170,505 shares during the period. Atle Fund Management AB bought a new stake in shares of Pyxis Oncology in the fourth quarter worth $710,000. Bank of America Corp DE increased its position in Pyxis Oncology by 2,690.9% during the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after acquiring an additional 593,853 shares during the last quarter. Longaeva Partners L.P. purchased a new stake in Pyxis Oncology during the third quarter valued at $1,117,000. Finally, Jane Street Group LLC lifted its holdings in Pyxis Oncology by 158.8% in the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after acquiring an additional 482,310 shares during the period. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.